All In Biotech

Drug Trial Radar · NCT06539182

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 155 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

155

Planned (sponsor's estimate)

Start

Apr 29, 2024

Primary completion

Sep 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will treat patients with CLL/SLL whose disease comes back or is not responding to prior therapy, or if they can not bear side effects of the prior treatment. This study will assess the anti-tumor activity of DZD8586 as monotherapy. It will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body.

Conditions

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

  • DZD8586Drug

    Daily oral dose of DZD8586 at 25 mg.

  • DZD8586Drug

    Daily oral dose of DZD8586 at 50 mg.

  • DZD8586Drug

    Daily oral dose of DZD8586 at 75 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate assessed by investigatorsTime frame: assessed up to 2 years

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Hefei, Anhui, China · Recruiting

  • Research Site

    Beijing, Beijing Municipality, China · Recruiting

  • Research Site

    Beijing, Beijing Municipality, China · Recruiting

  • Research Site

    Guangzhou, Guandong, China · Recruiting

  • Research Site

    Guangzhou, Guandong, China · Recruiting

  • Research Site

    Zhengzhou, Henan, China · Recruiting

  • Research Site

    Wuhan, Hubei, China · Recruiting

  • First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Research Site

    Changchun, Jilin, China · Recruiting

  • Research Site

    Dalian, Liaoning, China · Not yet recruiting

  • Research Site

    Shenyang, Liaoning, China · Recruiting

  • Research Site

    Jinan, Shandong, China · Recruiting

  • Research Site

    Linyi, Shandong, China · Recruiting

  • Research Site

    Shanghai, Shanghai Municipality, China · Recruiting

  • Research Site

    Taiyuan, Shangxi, China · Recruiting

  • Research Site

    Tianjin, Tianjin Municipality, China · Recruiting

  • Research Site

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.